Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | SORD | Q00796 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203253 | 0.86 | KDM4E (0.67) | KDM4EMAPTSORDHTR1ADRD2 | |
| SCHEMBL6884485 | 0.84 | KDM4E (0.65) | KDM4EMAPTSORDHTR1ADRD2 | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL250876 | 0.84 | KDM4E (0.97) | KDM4EMAPTSORDHTR1ADRD2 | |
| SCHEMBL11637734 | 0.84 | KDM4E (0.65) | KDM4EMAPTSORDHTR1ADRD2 | |
| SCHEMBL20428029 | 0.84 | KDM4E (0.65) | KDM4EMAPTSORDHTR1ADRD2 | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL29432928 | 0.84 | KDM4E (0.97) | KDM4EMAPTSORDHTR1ADRD2 | |
| SCHEMBL13591224 | 0.84 | KDM4E (0.65) | KDM4EMAPTSORDHTR1ADRD2 | |
| SCHEMBL9722339 | 0.84 | KDM4E (0.88) | KDM4EMAPTSORDHTR1ADRD2 | |
| SCHEMBL2539346 | 0.84 | KDM4E (0.60) | KDM4EMAPTSORDHTR1ADRD2 | |
| SCHEMBL7777530 | 0.83 | KDM4E (0.56) | KDM4EMAPTSORDHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547452-B2 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080069885-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080063721-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7118763-B2 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES CONTROLLED THERAPEUTICS, INC. II (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060182810-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
| CN-1223348-C | N-(aryloxy group alkyl) heteroaromatic guadine and heteroaromatic guazine used as medicines | AVENTIS MEDICINES INC (US) | 2005-10-19 | — | — | CN | disclosed |
| US-20050025828-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES CONTROLLED THERAPEUTICS INC. II (US) | 2005-02-03 | — | — | US | disclosed |
| EP-0729357-B1 | MICROENCAPSULATED 1,2-BENZAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-02 | — | — | EP | disclosed |
| US-6803055-B2 | SUSTAINED RELEASE; BENZAZOLE RING STRUCTURE; PSYCHOLOGICAL DISORDERS | ALKERMAS CONTROLLED THERAPEUTICS INC. II | 2004-10-12 | — | — | US | disclosed |
| US-20030165571-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | ALKERMES CONTROLLED THERAPEUTICS INC. II (US) | 2003-09-04 | — | — | US | disclosed |
| EP-0357134-A1 | Antihypertensive 3-piperidinyl-indazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-03-07 | — | — | EP | disclosed |
| US-4804663-A | PSYCHOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-02-14 | — | — | US | disclosed |
| US-4804663-A | PSYCHOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-02-14 | — | — | US | disclosed |
| EP-0196132-A2 | 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-01 | — | — | EP | disclosed |
| EP-0196132-A2 | 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-01 | — | — | EP | disclosed |
| CN-86101906-A | Process for preparing 1, 2 benzisoxazol-3-yl and 1, 2 benzisothiazol-3-yl derivatives | — | 1986-10-01 | — | — | CN | disclosed |
| US-4558056-A | PSYCHOLOGICAL DISORDERS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-12-10 | — | — | US | disclosed |
| US-4524074-A | TREATMENT OF PSYCHOSES | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-06-18 | — | — | US | disclosed |
| EP-0127167-A2 | 3-(4-Piperidinyl)-1,2-benzisothiazoles and derivatives, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1984-12-05 | — | — | EP | disclosed |
| US-4458076-A | ANALGESICS, ANTIPSYCHOTICS | HOECHST-ROUSSEL PHARMACEUTICALS (US) | 1984-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080069885-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | HTR2B, HTR7, HTR3D | KDM4E 2185/4885MAPT 1127/4885HPGD 1345/4885 |
| US-20050025828-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | CYP4X1, P2RX5, P2RX1 | KDM4E 1915/4885MAPT 3126/4885HPGD 1955/4885 |
| US-20060182810-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | CYP4X1, P2RX5, P2RX1 | KDM4E 1915/4885MAPT 3126/4885HPGD 1955/4885 |
| US-20030165571-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | CYP4X1, P2RX5, P2RX1 | KDM4E 1915/4885MAPT 3126/4885HPGD 1955/4885 |
| US-20080063721-A1 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | HTR7, HTR2B, HTR1A | KDM4E 2558/4885MAPT 1235/4885HPGD 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.